Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composite enzyme apophlegmatisant

A technology of compound enzyme and protease, applied in the field of medicine, can solve the problem that the marketed phlegm-relieving drugs have not yet appeared, and achieve the effect of protecting biological activity and improving ability

Inactive Publication Date: 2010-09-01
郑昌学
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But so far, no phlegm-reducing drug on the market with deoxyribonuclease as the main ingredient or one of the main ingredients has not yet appeared.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composite enzyme apophlegmatisant

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Freeze-dried preparation: Dissolve 10 mg of hemolytic streptococcus dornase powder, 5 mg of bovine pancreatic deoxyribose nuclease I powder and 15 mg of subtilisin powder in 10 mL of normal saline, add 5 mg of calcium lactate and 5 g of lactose, fully dissolve and use dilute Adjust the pH value to 7.2 with sodium hydroxide, freeze-dry overnight in a -16°C freeze-dryer, and dispense. When used, dissolve the lyophilized preparation with 2-10mL of physiological saline for one dose (tracheal instillation, inhalation or oral spray).

Embodiment 2

[0024] Tablet: Add 1g porcine pancreatic DNase I powder, 1g earthworm DNase EWD1, 500mg papain powder, 100mg silkworm chrysalis protease, 200mg pepsin, 10g calcium carbonate and 35g leucine to 150g sorbitol sugar, After stirring and mixing, the tablet preparation can be combined enzyme-resolving phlegm buccal tablet (each tablet contains 10000 units of papain, 2000 units of silkworm chrysalis protease, 4000 units of pepsin, 4000 units of bovine pancreas deoxyribonuclease I and 4000 units of earthworm deoxyribonucleic acid Enzyme EWD1, take 1-2 tablets each time).

Embodiment 3

[0026] Powder spray: Dissolve 1g of citric acid in 1000mL of normal saline, add 200mg of recombinant human deoxyribonuclease I, 10mg of Serratia protease, 10mg of Streptococcus griseus protease and stir to dissolve, then add 15 grams of mannitol, 2 grams of Su Amino acid, fully dissolved and spray-dried to obtain compound enzyme powder, which is divided into hard capsules for powder inhalation. The inhalation amount of each capsule contains 2000 units of Serratia protease, 1000 units of Streptococcus griseus protease and 2000 units of Streptococcus griseus protease. Unit Recombinant Human Deoxyribonuclease I.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a composite enzyme apophlegmatisant and belongs to the technical field of medicament. The apophlegmatisant is a solid preparation or a liquid preparation which is prepared from combination of one or more deoxyribonuclease and one or more protease and a medicinal auxiliary material; in a solid preparation prescription, the mass proportion (W / W) of the deoxyribonuclease, the protease to the medicinal auxiliary material is 1 to (0.1-1) to (50-2,000); and in a liquid preparation prescription, the mass proportion (W / W, excluding water, a propellent and other cosolvents) of the deoxyribonuclease, the protease to the medicinal auxiliary material is 1 to (0.1-1) to (0.01-100). The composite enzyme apophlegmatisant can effectively remove sputum, especially thick sputum in oral cavity, laryngeal and trachea so as to overcome the block of the sputum to respiration.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the prescription, preparation and clinical application of enzyme-type phlegm-reducing medicine, especially the prescription, preparation and preparation method of compound enzyme-reducing phlegm medicine composed of protease and deoxyribonuclease (DNase). Background technique [0002] Under normal physiological conditions, sputum is the main form of self-cleaning of the respiratory tract. However, in pathological conditions, such as pneumonia, bronchitis, lung cancer, etc., sputum can cause various physiological reactions due to its viscosity and irritation. , poor breathing, etc., in severe cases, it may even cause tracheal obstruction, which threatens the life of the patient. Therefore, an important component in the treatment of respiratory diseases is to reduce phlegm. [0003] The viscosity of sputum mainly comes from one of its components - mucin. At present, t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/48A61K9/08A61P11/12A61K38/46
Inventor 郑昌学刘征张洪碧
Owner 郑昌学
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products